Lumicell is specializing in the field of image-guided cancer surgery. The company's technology illuminates cancer cells in the tumor cavity, enabling physicians to take action in real-time to improve patient outcomes. The company's lead product, consisting of a fluorescent optical contrast agent and a handheld illumination device, is currently under clinical investigation in patients undergoing breast cancer surgery. A planned pivotal study aims to evaluate the ability of the technology to reduce positive margin rates and reduce repeat surgeries while sparing healthy tissue. Lumicell technology is also being investigated in colorectal cancer, Barrett’s Esophagus, pancreatic cancer, and brain metastases. In clinical studies to date, no cancer has been missed and the safety profile of the optical contrast agent has been demonstrated. Lumicell was founded in 2008 and is based in Newton, MA, USA.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

University Health Network (UHN) is a healthcare and medical research organization in Toronto, Ontario, Canada. It is the largest such research organization in Canada and North America, ranking first in Canada for total research funding. It was named Canada's top research hospital by Research Infosource in 2015, 2016 and 2017. It was created in 1986 by the Government of Ontario through the merger of four major hospitals: Toronto General Hospital, Toronto Western Hospital, with the Princess Margaret Cancer Centre, and the Toronto Rehabilitation Institute merged in with The Toronto Hospital in 1999 and the name changed to the University Health Network. All four hospitals are affiliated with the Faculty of Medicine at the University of Toronto and serve as teaching hospitals for resident physicians, nurses, and other healthcare professions. UHN also operates The Michener Institute, an applied health sciences college that opened in 1958.

CritiTech conducts research and development into the production and application of fine-particle compounds. It has expanded its operations to include applications in fine particle api production, coatings, and internal product development. Their unique particle engineering innovation and expertise as well as their demonstrated experience in delivering high-quality, on-time results.

SenoRx, Inc. was formerly known as BiopSolation Medical, Inc. and changed its name to SenoRx, Inc. in April 1998. The company was incorporated in 1998 and is headquartered in Irvine, California. As of July 6, 2010, SenoRx, Inc. operates as a subsidiary of Bard Peripheral Vascular, Inc. They develop, manufacture and sell minimally-invasive medical devices for the diagnosis of breast cancer. Their initial product focus has been biopsy systems and breast tissue markers. They also are developing products for use in the treatment of breast cancer.

Pharmaco-Kinesis Corporation is a medical device company that aims to optimize the healing of the human body through proprietary local Smart Drug Delivery Systems™ (SDDS) and associated advanced devices to measure biological responses. Its product, Metronomic Biofeedback Pump™ (MBP) is a potentially revolutionary implantable infusion pump for local drug delivery that uses advanced microfluidic, diagnostic, and control mechanisms to deliver a variable, remotely programmable, a metronomic combination of tumor-fighting medications. The company was founded in 2006 and is headquartered in Inglewood, California.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

OncoFluor, Inc. provides methods for imaging and treating of organs and tissues. The company is headquartered in Coronado, CA

KB Medical is a Swiss company focusing on design, development, and commercialization of the AQrate robotic system for assisting surgeons during the spinal surgery. Its AQrate robotic system’s technology and intellectual property empowers spinal surgeons with precise, cost-effective, robotic-assisted spinal fusion in a less hazardous work environment. KB Medical improves patients’ outcome and quality of life after a spinal fusion surgery as well as to reduce the received radiation by the OR team during the surgery. It is certified for the design and manufacture of assisted robotic system for spinal surgery accordingly to ISO 13485. KB Medical is based in Ecublens, Switzerland.

Genomic Health, Inc. (NASDAQ: GHDX) is a provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland.

Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.

TesoRx is a virtual pharmaceutical company developing and commercializing pharmaceutical products. The company engages in developing and commercializing pharmaceutical products. It develops TSX-002, an oral therapeutic testosterone formulation for use in testosterone deficiency in men. The company was incorporated in 2010 and is based in Menlo Park, California.

Tepha is a medical device firm pursuing the development and commercialization of innovative products based on the company's proprietary biomaterial technology. The technology provides a new class of absorbable biomaterials, known as polyhydroxyalkanoates , which may be tailored to meet unmet needs for medical devices in multiple fields. Tepha's novel, biosynthetically produced materials offer superior performance in flexibility, elasticity, and biocompatibility; and, for its fiber-based products, excellent tensile strength and strength retention.

Agalimmune Ltd., a subsidiary of BioLineRx Ltd., is a British company located in London that develops anti-cancer immunotherapy technology. It was founded by Graham Griffiths. Mike Westby is currently the CEO of the firm. BioLineRx Ltd. acquired Agalimmune Ltd. on March 23, 2017 for $6.05 million.

Hangzhou Huamai Medical Technology Co., Ltd., established on 2016-12-21, Business scope includes general items:Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Manufacturing of bio-based materials;Sales of bio-based materials(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Portola Medical, Inc., part of Huiheng Medical, Inc., is an American company. The firm manufactures and distributes large radiation oncology medical equipment used for the treatment of cancer and tumors. On June 07, 2010 Huiheng Medical, Inc. acquired Portola Medical, Inc. for $0.26 million.